Publications

452 publications

Enter search criteria
Fill in keyword(s) to narrow your search.
Period
You can select a specific type of a publication you are looking for, such as press releases or speeches
Sort by:
  1. GVS advice on finerenon (Kerendia®)

    The National Health Care Institute advises the Minister to include finerenon (Kerendia®) in List 1B of the GVS. Finerenon is ...

    Report | 04-04-2022

  2. GVS advice extension further conditions for dapagliflozin (Forxiga®)

    The National Health Care Institute has completed its assessment whether the further conditions for dapagliflozin (Forxiga®) could ...

    Report | 28-03-2022

  3. GVS advice extension further conditions for elexacaftor/tezacaftor/ivacaftor (Kaftrio®) in combination with ivacaftor (Kalydeco®)

    The National Health Care Institute has completed its assessment whether the further conditions of ...

    Report | 22-03-2022

  4. Package advice cabozantinib in combination with nivolumab (Cabometyx-Opdivo®)

    The National Health Care Institute advises the Minister to include cabozantinib in combination with nivolumab (Cabometyx® in ...

    Report | 14-03-2022

  5. GVS advice liraglutide (Saxenda®), extension of further conditions for certain people with an extremely increased weight-related health risk

    The National Health Care Institute advises the Minister to extend the List 2 conditions for liraglutide (Saxenda®). The ...

    Report | 24-02-2022

  6. GVS advice vericiguat (Verquvo®) for the treatment of symptomatic chronic heart failure

    The National Health Care Institute advises the Minister not to include vericiguat (Verquvo®) in the Medicine Reimbursement System ...

    Report | 24-02-2022

  7. GVS advice on cenobamate (Ontozry®) for the adjunctive treatment of focal-onset seizures

    The National Health Care Institute advises the Minister to include cenobamate (Ontozry®) in List 1A of the GVS. Cenobamate is ...

    Report | 22-02-2022

  8. GVS advice ofatumumab (Kesimpta®) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS)

    The National Health Care Institute advises the Minister to include ofatumumab (Kesimpta®) on List 1B of the GVS. Ofatumumab is ...

    Report | 10-02-2022

  9. Package advice tisagenlecleucel (Kymriah®) for the treatment of r/r DLBCL

    The National Health Care Institute has completed its reassessment whether tisagenlecleucel (Kymriah®) can be included in the ...

    Report | 25-01-2022

  10. Package advice tucatinib (Tukysa®)

    The National Health Care Institute has completed its assessment whether tucatinib (Tukysa®) in combination with trastuzumab and ...

    Report | 17-01-2022